Polymedco Introduces Point Of Care Test For Recurrent Bladder Cancer Detection

Armen Hareyan's picture

Bladder Cancer Detection

Polymedco Inc. is pleased to announce the introduction of the BTA stat test -- a point of care technology for the early detection of recurrent bladder cancer.

This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. The specificity of the BTA stat test was 93-95% in patients with non-genitourinary diseases and cancers and healthy individuals tested as part of a multi-center study.


The test has a sensitivity that is considerably higher than voided urine cytology, enabling detection of recurrent early stage and grade cancers that cytology often misses. Requiring five drops of urine, the result is delivered in only five minutes. The appearance of a line in the patient window indicates a positive result. The BTA stat test requires one voided urine sample with no sample preparation.

Bladder cancer is the fourth most common cancer among men and tenth among females. 57,400 people will be diagnosed with the disease in 2007. It has a 5-year survival rate of 94% if caught early and recurs in over 88% of patients within fifteen years, calling for regular testing and lifelong management.

Polymedco, Inc. is one of the leading marketing and distribution companies in the clinical laboratory marketplace.